Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Lancet Infect Dis. 2016 Jun;16(6):735–745. doi: 10.1016/S1473-3099(16)00120-1

Table 1.

Available results of DAA-based regimens to treat HCV recurrence after liver transplantation

Regimen Study N Genotype Cirrhosis (%) SVR12 Author (ref)
SOFOSBUVIR+RIBAVIRIN
24 weeks		 Prospective
Multicenter
Open-label		 40 All (83% G1) Yes (40%) 70% Charlton, M. 65
SOFOSBUVIR+DACLATASVIR+RIBAVIRIN
12 weeks (ALLY-1)		 Prospective
Multicenter
Open-label		 53 All (77% G1) Yes 94% Poordad, F. 39
SOFOSBUVIR+DACLATASVIR±RIBAVIRIN
12 or 24 weeks (ANRS CO23 CUPILT)		 Prospective
Multicenter
Real-life cohort		 130 All (82% G1) Yes (31%) 96% Coilly, A. 70
PARITAPREVIR+OMBITASVIR/r+DASABUVIR+ RIBAVIRIN
24 weeks		 Prospective
Multicenter
Open-label		 34 Only G1 No 97% Kwo, PY. 74
SOFOSBUVIR+LEDIPASVIR+RIBAVIRIN
12 or 24 weeks (SOLAR I and II)		 Prospective randomized phase II study 444 G1 (>95%) and G4 Yes (about 50%) 92% Charlton, M. 37
Manns, M. 38
SOFOSBUVIR+SIMEPREVIR±RIBAVIRIN
12 weeks		 Prospective
Multicenter
Open-label		 109 Only G1 F3–F4 (29%) 90% Pungpapong, S. 143
SOFOSBUVIR+SIMEPREVIR±RIBAVIRIN
12 weeks (HCV-TARGET)		 Prospective
Multicenter
Real-life cohort		 143 All (80% G1) Yes (56%) 90% (SVR4) Sulkowski, M. 144